Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say

1st April 2019 Uncategorised 0

Many years into an investigation focusing on Opana ER generic delays, the Federal Trade Commission says Impax violated competition law by striking a deal with the brand’s maker, Endo, to put off its copycat launch in exchange for cash.

More: Impax in hot water for 'pay-for-delay' deal on Endo painkiller Opana ER, feds say
Source: fierce